Lewczuk Piotr, Hornegger Joachim, Zimmermann Rüdiger, Otto Markus, Wiltfang Jens, Kornhuber Johannes
Department of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen, Schwabachanlage 6, Erlangen, Germany.
Eur Arch Psychiatry Clin Neurosci. 2008 Nov;258 Suppl 5:44-9. doi: 10.1007/s00406-008-5005-3.
In this review, current neurochemical dementia diagnostics (NDD) procedures are presented with a focus on biomarkers in the cerebrospinal fluid (CSF) and blood: amyloid beta peptides, tau protein, and its phosphorylated form (pTau). CSF analysis is an increasingly important tool for early and differential diagnosis of dementia syndromes. Although lumbar puncture is a mildly invasive procedure with a low incidence of complications, establishing blood assays capable of reliably measuring NDD biomarkers is an aim of several studies worldwide.
在本综述中,介绍了当前的神经化学性痴呆诊断(NDD)程序,重点关注脑脊液(CSF)和血液中的生物标志物:淀粉样β肽、tau蛋白及其磷酸化形式(pTau)。脑脊液分析是痴呆综合征早期和鉴别诊断中日益重要的工具。尽管腰椎穿刺是一种侵入性较小、并发症发生率较低的操作,但建立能够可靠测量NDD生物标志物的血液检测方法是全球多项研究的目标。